DRUG.CX Quote, Financials, Valuation and Earnings

Green Thumb Industries, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of 8.17%. Bright Minds Biosciences, Inc.'s return on equity of -25.19% beat Green Thumb Industries, Inc.'s return on equity of 2.53%.

Bright Minds Biosciences, Inc. has a consensus price target of $89.67, signalling downside risk potential of -22.41%. On the other hand Green Thumb Industries, Inc. has an analysts' consensus of $17.51 which suggests that it could grow by 65.22%. Given that Green Thumb Industries, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Green Thumb Industries, Inc. is more attractive than Bright Minds Biosciences, Inc..

Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Green Thumb Industries, Inc. has a beta of 0.833, suggesting its less volatile than the S&P 500 by 16.713%.

Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Green Thumb Industries, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Green Thumb Industries, Inc. pays out -- of its earnings as a dividend.

Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Green Thumb Industries, Inc. quarterly revenues of $401.3M. Bright Minds Biosciences, Inc.'s net income of -$5.2M is lower than Green Thumb Industries, Inc.'s net income of $32.8M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Green Thumb Industries, Inc.'s PE ratio is 41.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 1.55x for Green Thumb Industries, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Lowell Farms, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of -111.87%. Bright Minds Biosciences, Inc.'s return on equity of -25.19% beat Lowell Farms, Inc.'s return on equity of -182.5%.

Bright Minds Biosciences, Inc. has a consensus price target of $89.67, signalling downside risk potential of -22.41%. On the other hand Lowell Farms, Inc. has an analysts' consensus of -- which suggests that it could grow by 19875.27%. Given that Lowell Farms, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Lowell Farms, Inc. is more attractive than Bright Minds Biosciences, Inc..

Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Lowell Farms, Inc. has a beta of 1.815, suggesting its more volatile than the S&P 500 by 81.503%.

Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lowell Farms, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Lowell Farms, Inc. pays out -- of its earnings as a dividend.

Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Lowell Farms, Inc. quarterly revenues of $4.4M. Bright Minds Biosciences, Inc.'s net income of -$5.2M is lower than Lowell Farms, Inc.'s net income of -$5M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Lowell Farms, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 0.01x for Lowell Farms, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Vireo Growth, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of -28.69%. Bright Minds Biosciences, Inc.'s return on equity of -25.19% beat Vireo Growth, Inc.'s return on equity of -52.07%.

Bright Minds Biosciences, Inc. has a consensus price target of $89.67, signalling downside risk potential of -22.41%. On the other hand Vireo Growth, Inc. has an analysts' consensus of -- which suggests that it could fall by -17.72%. Given that Bright Minds Biosciences, Inc. has more downside risk than Vireo Growth, Inc., analysts believe Vireo Growth, Inc. is more attractive than Bright Minds Biosciences, Inc..

Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Vireo Growth, Inc. has a beta of 0.001, suggesting its less volatile than the S&P 500 by 99.895%.

Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vireo Growth, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Vireo Growth, Inc. pays out -- of its earnings as a dividend.

Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Vireo Growth, Inc. quarterly revenues of $126.2M. Bright Minds Biosciences, Inc.'s net income of -$5.2M is higher than Vireo Growth, Inc.'s net income of -$36.2M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Vireo Growth, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 1.58x for Vireo Growth, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Wesana Health Holdings has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -25.19% beat Wesana Health Holdings's return on equity of --.

Bright Minds Biosciences, Inc. has a consensus price target of $89.67, signalling downside risk potential of -22.41%. On the other hand Wesana Health Holdings has an analysts' consensus of -- which suggests that it could grow by 2383.25%. Given that Wesana Health Holdings has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Wesana Health Holdings is more attractive than Bright Minds Biosciences, Inc..

Bright Minds Biosciences, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Wesana Health Holdings has a beta of -1.000, suggesting its less volatile than the S&P 500 by 200.004%.

Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Wesana Health Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Wesana Health Holdings pays out -- of its earnings as a dividend.

Bright Minds Biosciences, Inc. quarterly revenues are --, which are larger than Wesana Health Holdings quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$5.2M is higher than Wesana Health Holdings's net income of --. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Wesana Health Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 0.39x for Wesana Health Holdings. Usually stocks with elevated PS ratios are considered overvalued.